Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxytocin
Drug ID BADD_D01652
Description Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906.[A229008,A228593,A229108] Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues.[A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work.[A229108] Oxytocin continues to be an important tool in modern obstetrics to induce labor when indicated and to manage postpartum hemorrhage.[A229108,A229113] It is estimated that labor induction with oxytocin is used in almost 10% of deliveries globally.[A228593] It should be noted that there are risks associated with oxytocin intervention during childbirth. Oxytocin should be used judiciously only when necessary and by experienced healthcare practitioners.[A229113] Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects.[A229008] It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning.[A229013] Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.[A228593,A229098]
Indications and Usage Administration of exogenous oxytocin is indicated in the antepartum period to initiate or improve uterine contractions for vaginal delivery in situations where there is fetal or maternal concern.[L31433] For example, It may be used to induce labor in cases of Rh sensitization, maternal diabetes, preeclampsia at or near term, and when delivery is indicated due to prematurely ruptured membranes.[A229018,L31433] Importantly, oxytocin is not approved or indicated for elective induction of labor. Oxytocin may be used to reinforce labor in select cases of uterine inertia and as adjunctive therapy in the management of incomplete or inevitable abortion. In the postpartum period, oxytocin may be used to induced contractions in the 3rd stage of labor and to control postpartum bleeding or hemorrhage.[L31433]
Marketing Status approved; vet_approved
ATC Code H01BB02
DrugBank ID DB00107
KEGG ID D00089
MeSH ID D010121
PubChem ID 439302
TTD Drug ID D0M3FJ
NDC Product Code 0641-6115; 41701-017; 70155-001; 42023-130; 41701-002; 0143-9743; 0143-9742; 55154-9584; 63323-012; 0641-6114; 60870-0438; 73212-021; 76617-011; 62991-3133; 75882-213; 42023-116; 14403-0015; 46600-0001; 49452-4956; 51927-0281; 64189-1202; 38779-2492; 51552-0631
UNII 1JQS135EYN
Synonyms Oxytocin | Ocytocin | Syntocinon | Pitocin
Chemical Information
Molecular Formula C43H66N12O12S2
CAS Registry Number 50-56-6
SMILES CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3C CCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute pulmonary oedema22.01.03.005; 02.05.02.004--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Apgar score low13.15.01.012--Not Available
Arrhythmia02.03.02.001--Not Available
Asphyxia22.02.02.001; 12.01.08.011--Not Available
Bradycardia02.03.02.002--Not Available
Coma17.02.09.001--Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Electrocardiogram QT prolonged13.14.05.004--
Factor I deficiency03.15.01.001; 01.01.01.003--Not Available
Flushing24.03.01.002; 08.01.03.025; 23.06.05.003--
Foetal distress syndrome18.03.02.003--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia15.05.04.007; 17.05.02.001--Not Available
Hypervolaemia02.05.04.019; 14.05.06.003--Not Available
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Jaundice neonatal09.01.01.008; 01.06.04.006; 18.04.08.001--Not Available
Muscle spasms15.05.03.004--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nausea07.01.07.001--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene